Rebound tonometer comparable to Goldmann applanation

Article

IOP measurements obtained with the rebound tonometer (Icare Pro) are more comparable to those achieved with the Goldmann applanation tonometer than those obtained with ultra-high-speed Scheimpflug technology, according to a recent study.

IOP measurements obtained with the rebound tonometer (Icare Pro) are more comparable to those achieved with the Goldmann applanation tonometer than those obtained with ultra-high-speed Scheimpflug technology, according to a study published in Investigative Ophthalmology & Visual Science (IOVS).

For this comparison study, researchers from the Medical University of Silesia, in Katowice, Poland, included 192 eyes of 96 patients, 152 of which were healthy and measured IOPs using the Goldmann applanation tonometer (GAT), a rebound tonometer (RT; Icare PRO), and ultra-high-speed Scheimpflug Technology (UHS ST). Corneal pachymetry was also done with a Scheimpflug camera and an ultrasound pachymeter (A-scan Plus, Accutome) as a comparison for Corvis ST pachymetry.

Mean IOPs were 15.6 mmHg (GAT), 15.6 mmHg (RT), and 16.1 mmHg (UHS ST). Mean central corneal thickness (CCT) was 543.7 μm (UHS ST), 547.9 μm (Pentacam) and 556.25 μm (ultrasound pachymeter).

Researchers noted a significant difference between IOP measurements obtained with GAT and RT compared to measurements obtained with the UHS ST (P P = 0.5). In addition, no significant differences were seen in CCT measured via UHS ST, Pentacam and ultrasound pachymeter.

To access the abstract of this study, click here.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
© 2025 MJH Life Sciences

All rights reserved.